Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.

Jennifer G. Robinson | C. Carlson | R. Marioni | M. Fornage | O. Franco | A. Hofman | A. Uitterlinden | A. Reiner | D. Levy | I. Deary | J. Pankow | Mingyao Li | E. Boerwinkle | W. Kraus | M. Farrall | V. Gudnason | Qunyuan Zhang | I. Borecki | Albert Vernon Smith | A. Dehghan | Svati H Shah | M. Reilly | D. Rader | D. Girelli | N. Martinelli | K. Lohman | Yongmei Liu | B. Psaty | D. Siscovick | S. Kathiresan | O. Melander | M. Orho-Melander | K. Taylor | J. Rotter | D. Ardissino | J. Ordovás | T. Harris | I. Rudan | J. Brody | J. Starr | K. Rice | A. Isaacs | C. V. van Duijn | L. Cupples | J. Robinson | C. O’Donnell | R. Jackson | U. Peters | R. McPherson | G. Peloso | H. Watkins | James G. Wilson | J. Bis | O. Gottesman | E. Bottinger | S. Rich | G. Davies | C. Hayward | O. Polašek | G. Eiriksdottir | L. Launer | M. Feitosa | A. Goel | A. Correa | P. Schreiner | C. Kooperberg | A. Morrison | N. Stitziel | R. Loos | A. Voorman | R. Mackey | M. Griswold | P. Auer | Yingchang Lu | M. Grove | L. Lange | A. Patel | Jacy R. Crosby | H. Taylor | Y. I. Chen | A. Manichaikul | J. Mychaleckyj | L. Reynolds | S. Duga | J. Huffman | J. Jakobsdóttir | S. Demissie | P. Merlini | B. Davis | R. Asselta | J. Stafford | G. Hindy | M. Tsai | Aron Y Joon | Sumeet A. Khetarpal | P. Zanoni | V. Redon | Kim S Lawson | K. Ryckman | Judy Wang | Svati H. Shah | A. Smith | Aron Y. Joon | S. Shah | R. Jackson | A. Smith | A. Uitterlinden | A. Hofman | K. Taylor | Arend Voorman | K. Taylor | R. Jackson

[1]  E. Boerwinkle,et al.  dbNSFP v2.0: A Database of Human Non‐synonymous SNVs and Their Functional Predictions and Annotations , 2013, Human mutation.

[2]  Eric Boerwinkle,et al.  Best Practices and Joint Calling of the HumanExome BeadChip: The CHARGE Consortium , 2013, PloS one.

[3]  Jonathan C. Cohen,et al.  Simple Genetics for a Complex Disease , 2013, Science.

[4]  D. Melton,et al.  RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation , 2013, Cell.

[5]  A. Abou-Samra,et al.  Emerging roles of Lipasin as a critical lipid regulator. , 2013, Biochemical and Biophysical Research Communications - BBRC.

[6]  Ian J Deary,et al.  Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. , 2012, International journal of epidemiology.

[7]  Jonathan C. Cohen,et al.  Atypical angiopoietin-like protein that regulates ANGPTL3 , 2012, Proceedings of the National Academy of Sciences.

[8]  Patrick F. Sullivan,et al.  zCall: a rare variant caller for array-based genotyping: Genetics and population analysis , 2012, Bioinform..

[9]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[10]  Adam Kiezun,et al.  Exome sequencing and the genetic basis of complex traits , 2012, Nature Genetics.

[11]  Nilesh J Samani,et al.  A Genome-Wide Association Study for Coronary Artery Disease Identifies a Novel Susceptibility Locus in the Major Histocompatibility Complex , 2012, Circulation. Cardiovascular genetics.

[12]  R Bailén Almorox,et al.  [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol]. , 2012, Revista clinica espanola.

[13]  Xihong Lin,et al.  Rare-variant association testing for sequencing data with the sequence kernel association test. , 2011, American journal of human genetics.

[14]  Toshiko Tanaka,et al.  Novel association to the proprotein convertase PCSK7 gene locus revealed by analysing soluble transferrin receptor (sTfR) levels. , 2011, Human molecular genetics.

[15]  T. Assimes,et al.  Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies , 2011, The Lancet.

[16]  S. Young,et al.  Deletion of the Basement Membrane Heparan Sulfate Proteoglycan Type XVIII Collagen Causes Hypertriglyceridemia in Mice and Humans , 2010, PloS one.

[17]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[18]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[19]  I. Rudan,et al.  Genome-wide association study of biochemical traits in Korcula Island, Croatia. , 2009, Croatian medical journal.

[20]  Alberto Piazza,et al.  Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.

[21]  K. Lunetta,et al.  Methods in Genetics and Clinical Interpretation Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Design of Prospective Meta-Analyses of Genome-Wide Association Studies From 5 Cohorts , 2010 .

[22]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[23]  S. Leal,et al.  Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. , 2008, American journal of human genetics.

[24]  Olle Melander,et al.  Polymorphisms associated with cholesterol and risk of cardiovascular events. , 2008, The New England journal of medicine.

[25]  P. Visscher,et al.  The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond , 2007, BMC geriatrics.

[26]  V. Gudnason,et al.  Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. , 2007, American journal of epidemiology.

[27]  A. Prat,et al.  The proprotein convertases and their implication in sterol and/or lipid metabolism , 2006, Biological chemistry.

[28]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[29]  Nuala A Sheehan,et al.  Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure , 2005, Statistics in medicine.

[30]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[31]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[32]  Daniel W. Jones,et al.  Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. , 2005, Ethnicity & disease.

[33]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[34]  A. Hofman,et al.  Determinants of disease and disability in the elderly: The Rotterdam elderly study , 1991, European Journal of Epidemiology.

[35]  Garnet L Anderson,et al.  The Women's Health Initiative recruitment methods and results. , 2003, Annals of epidemiology.

[36]  Scott Davis,et al.  Implementation of the Women's Health Initiative study design. , 2003, Annals of epidemiology.

[37]  S. Rubin,et al.  Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). , 2003, The American journal of cardiology.

[38]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[39]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[40]  Z. Derewenda,et al.  The structure and function of platelet-activating factor acetylhydrolases , 1998, Cellular and Molecular Life Sciences CMLS.

[41]  G. Zimmerman,et al.  Platelet-activating Factor Acetylhydrolases* , 1997, The Journal of Biological Chemistry.

[42]  Keizo Inoue,et al.  Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer , 1997, Nature.

[43]  D C Rao,et al.  NHLBI Family Heart Study: objectives and design. , 1996, American journal of epidemiology.

[44]  L H Kuller,et al.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. , 1995, Annals of epidemiology.

[45]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[46]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[47]  G. R. Warnick,et al.  Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. , 1990, Clinical chemistry.

[48]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.

[49]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[50]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[51]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[52]  W. Kannel,et al.  Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.